Seres Therapeutics Inc (MCRB) concluded trading on Wednesday at a closing price of $0.40, with 4.46 million shares of worth about $1.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.16% during that period and on April 16, 2025 the price saw a loss of about -13.44%. Currently the company’s common shares owned by public are about 173.01M shares, out of which, 127.46M shares are available for trading.
Stock saw a price change of -25.39% in past 5 days and over the past one month there was a price change of -46.44%. Year-to-date (YTD), MCRB shares are showing a performance of -51.88% which decreased to -35.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.46 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Seres Therapeutics Inc shares is 1.29 million. The stock is currently trading -37.42% below its 20-day simple moving average (SMA20), while that difference is down -43.99% for SMA50 and it goes to -53.20% lower than SMA200.
Seres Therapeutics Inc (NASDAQ: MCRB) currently have 173.01M outstanding shares and institutions hold larger chunk of about 22.93% of that.
The stock has a current market capitalization of $69.72M and its 3Y-monthly beta is at 2.94. It has posted earnings per share of -$0.96 in the same period. It has Quick Ratio of 0.94 while making debt-to-equity ratio of 6.65. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MCRB, volatility over the week remained 20.39% while standing at 11.21% over the month.
Coverage by Oppenheimer stated Seres Therapeutics Inc (MCRB) stock as an Outperform in their note to investors on June 26, 2023, suggesting a price target of $12 for the stock. On April 21, 2023, JP Morgan Initiated their recommendations, while on July 23, 2021, Goldman Downgrade their ratings for the stock with a price target of $7. Stock get a Neutral rating from Goldman on May 18, 2021.
